Processa Pharmaceuticals PCSA Q4 2025 Earnings EPS Misses Estimates by a Wide Margin as PreRevenue Biotech Advances Pipeline ZENA Q4 2025 Earnings Massive EPS Miss Without Revenue Disclosure as Stock Surges 511 NGS Q1 2026 Earnings EPS Surprises to the Upside Amidst Solid Operational Execution TUSK Q1 2026 Earnings Return to Profitability Drives Shares Higher SUNC Q1 2026 Earnings Significant EPS Miss Raises Concerns CISS Q3 2025 Earnings Losses Widen as Stock Declines 512